Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy with or without one year of everolimus in patients with high-risk, hormone receptor- (HR) positive and HER2-neu-negative breast cancer: SWOG/NSABP S1207.
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: The University of Texas MD Anderson Cancer Center, Cancer Research And Biostatistics, UPMC Hillman Cancer Center, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, University of Michigan, NSABP Foundation, SWOG Cancer Research Network, University of Pittsburgh
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2586234556